[ad_1]
In the heart of Kerala, India, Sreekumar Raghavakaimal and his curiosity about the world bloomed amidst a family deeply affected by health-related misfortune. Witnessing the devastating impact of diabetes and cancer, in which the latter claimed the lives of both his father and brother, he vowed to fight back and dedicate himself to the intricacies of genetic diseases.
Decoding destiny may sound like an impossible feat. Still, Sreekumar Raghavakaimal’s rise in the ranks of genomic programming and sequencing aimed to do just that — unravel the mystery of genomics in complex diseases and find the root cause of their development through a whole genome approach.
With decades of clinical research experience under his belt, Raghavakaimal follows a valiant path of bringing reason to this misfortune and tapping into a realm of science that could save millions of lives soon.
Sreekumar Raghavakaimal is a scientific researcher known for innovative experimentations of organic compounds in the realm of pathophysiology. In other words, he’s dedicated his life to the research and development of genetic diseases and genomics’ role in systems biology. For over forty years, he’s faced various obstacles in his efforts while pacing alongside the breakthroughs and developments that have allowed him to continue on his path.
His credentials speak for themselves: a Master’s Degree in Chemistry & Physics from the University of Kerala, India, and a PhD in Organic Chemistry from the Indian Institute of Technology, Madras, India. He then relocated to the University of Wisconsin, Madison, to complete his post-doctoral training in Bioorganic Chemistry & Physiology.
Over the course of his studies, Raghavakaimal’s particular research interests have encompassed studying the pathophysiology of liver diseases, diabetes, cancer, and aging, as well as the genetic and proteomic (relating to proteins) bases for the development of these conditions. Additionally, he’s worked extensively with bioinformatic programs and biomarkers, which serve as early warning systems for potential health issues.
While ‘genetics’ is a household term and widely taught in schools, the study of genomics slightly differs in its context. Rather than focusing on single and specific genes as the field of genetics does, genomics relates to a person’s genome or the complete set of an organism’s genetic makeup. This field focuses on the structure, function, mapping, evolution, and editing of genomes collectively.
The field of genomics also employs high-throughput DNA sequencing and bioinformatics to unravel the mysteries of genomes, mapping their sequences and deciphering their functional and structural secrets. As advancements in this field continue, researchers gain revolutionary insights into some of the most complex biological systems, such as the brain and other vital organs.
As Raghavakaimal states, “Understanding the pathophysiology of any disease is the key to developing a potential drug for its treatment.” Studies show that genomics has opened the door to methodological advances in studying common and rare genetic variants in complex diseases. By fully sequencing human genomes, clinicians and scientists can understand the molecular basis for diseases such as diabetes and cancer.
As the Director of GCRC Genomics, Proteomics, and Metabolic Core Laboratory, Raghavakaimal has been instrumental in advancing genomics research. The laboratory extracts DNA from serum, tissue, and cell culture, performing DNA copy number measurement and genotyping analysis. He employed custom microarray analysis to understand the pathophysiology of various diseases and monitor treatment outcomes.
Additionally, as the Director of Mayo Genomic Center Microarray Core Laboratory, Raghavakaimal has used the Affymetrix platform for microarray analysis. This involves gene expression analysis using real-time polymerase chain reaction (PCR), contributing valuable insights into the molecular mechanisms for underlying diseases.
Finally, his substantial role as Senior Vice-President & Chief Development Officer at the National Foundation for Cancer Research has furthered the impact of genomics in cancer research. His efforts contribute to the ongoing advancements in genomics, pushing the boundaries of knowledge and paving the way for improved disease prevention, diagnosis, and treatment.
In the pursuit of unraveling complex genetic diseases, Sreekumar Raghavakaimal foresees a future grounded in precision medicine and personalized treatment. The evolution from understanding disease pathophysiology to advancing high-throughput genomics positions scientists at the threshold of a revolutionary era. The comprehensive analysis of an organism’s genetic makeup, coupled with artificial intelligence, holds the potential to unlock tailored interventions, marking a shift in how we approach and treat intricate conditions.
Integrating AI into genomic research is key in deciphering vast datasets, identifying subtle patterns, and unveiling novel insights into disease mechanisms. This synergy between advanced computational tools and human expertise promises innovative therapeutic strategies. A holistic approach, considering the interplay between genetics, environment, and lifestyle through multi-omics approaches, offers a nuanced perspective on disease development and progression.
Collaboration across scientific disciplines is central to shaping the future of genetic disease treatment. By bringing together genomics, bioinformatics, and clinical research, scientists can create a collaborative platform for development where expertise translates genomic insights into tangible clinical solutions.
Now, with over 50 peer-reviewed publications in national and international journals, Raghavakaimal’s work is nowhere close to finished. He plans to further his research in his related field and bring a long-awaited answer to the tragic circumstances that profoundly impacted his family’s lives.
According to Raghavakaimal, “The role of human genomics research and related biotechnologies has the potential to achieve a number of public health goals, such as to reduce global health inequalities by providing developing countries with efficient, cost-effective and robust means of preventing, diagnosing and treating major diseases that burden their populations.”
Sreekumar Raghavakaimal and his contributions to advancing genomics set the stage for a future where precision, personalization, and innovation converge to redefine the healthcare landscape. As scientists and researchers stand on the cusp of a genomic revolution, decoding destinies becomes a lifeline for millions facing the challenges of genetic diseases.
[ad_2]
Source link